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Abstract 
The hypothalamus plays a crucial role in body weight homeostasis through an intricate network of neuronal circuits 
that are under the precise regulation of peripheral hormones and central transmitters. Although deregulated function 
of such circuits might be a major contributing factor in obesity, the molecular mechanisms responsible for the 
hypothalamic control of energy balance remain partially unknown. MicroRNAs (miRNAs) have been recognized as 
key regulators of different biological processes, including insulin sensitivity and glucose metabolism. However, the 
roles of miRNA pathways in the control of metabolism have been mostly addressed in peripheral tissues, whereas the 
potential deregulation of miRNA expression in the hypothalamus in conditions of metabolic distress remains as yet 
unexplored. In this work, we used high-throughput screening to define to what extent the hypothalamic profiles of 
miRNA expression are perturbed in two extreme conditions of nutritional stress in male rats, namely chronic caloric 
restriction and high-fat diet–induced obesity. Our analyses allowed the identification of sets of miRNAs, including 
let-7a, mir-9*, mir-30e, mir-132, mir-145, mir-200a, and mir-218, whose expression patterns in the hypothalamus 
were jointly altered by caloric restriction and/or a high-fat diet. The predicted targets of these miRNAs include 
several elements of key inflammatory and metabolic pathways, including insulin and leptin. Our study is the first to 
disclose the impact of nutritional challenges on the hypothalamic miRNA expression profiles. These data will help to 
characterize the molecular miRNA signature of the hypothalamus in extreme metabolic conditions and pave the way 
for targeted mechanistic analyses of the involvement of deregulated central miRNAs pathways in the pathogenesis of 
obesity and related disorders. 
Metabolic syndrome is defined by a series of related disorders, including obesity, insulin resistance, 
glucose intolerance, and hyperlipidemia. Obesity is the major factor for the development of metabolic 
syndrome and has emerged as one of the most important medical problems of the 21st century, being also 
a major risk factor for the development of cardiovascular diseases and type 2 diabetes. According to 
World Health Organization estimates, type 2 diabetes affects 347 million people worldwide (1), and its 
prevalence continues to increase due to advancing age, inactivity, and increasing obesity rates (2). 
Contrary to the idea that obesity is triggered by the influence of isolated metabolic insults and/or 
merely by enhanced food intake, it has now become clear that obesity is a multifaceted condition in which 
genetic load, developmental programming, and environment are major contributing factors, together with 
specific gene-diet interactions (3, 4). During the past few decades, much of the effort in obesity research 
has been focused on the study of peripheral metabolic tissues, such as the white adipose tissue (WAT), 
liver, and muscle, because they function as the main sites of use and storage of nutrients and energy 
excess. However, data gleaned in recent years have highlighted the putative important role of 
neurohormonal deregulation in the pathogenesis of obesity (5–7), based on the essential roles that the 
central nervous system in general and the hypothalamus in particular play in energy homeostasis. Thus, 
discrete hypothalamic nuclei and circuits are essential for the control of food intake and sensing of 
multiple circulating peripheral signals such as leptin, insulin, adiponectin, gut hormones, and nutrients. 
These various signals function as metabolic “gauges” that interact with specific hypothalamic regions to 
modulate (or eventually perturb) energy balance both peripherally and centrally (8–10). Deregulation of 
such neuroendocrine homeostasis is likely to play a key role in the onset and progression of obesity. 
In particular, by signaling adiposity to the hypothalamus, insulin and leptin have been proven essential 
for the central inhibitory control of feeding; an action that is conducted in part by reducing the expression 
of orexigenic neuropeptides and increasing the expression of anorexigenic neuropeptides (11, 12). Leptin 
deficiency results in morbid obesity in both animals and humans (11, 13–15), and the central effects of 
leptin and insulin are very relevant for the regulation of circulating glucose levels (11, 16). However, 
obesity is associated with enhanced levels of leptin and insulin but decreased responses to endogenous 
and exogenous leptin and insulin, a phenomenon of resistance whose molecular basis has not been fully 
clarified. In addition, other peripheral hormones play a central role with leptin and insulin in the fine 
control of energy balance and metabolism (5, 17). 
In recent years, the functional importance of noncoding RNAs in the control of diverse biological 
processes has been recognized. In particular, microRNAs (miRNAs) are well-known regulators of the 
mammalian cell phenotype (18, 19). miRNAs are small, non–protein-coding RNAs that negatively 
regulate gene expression by promoting degradation and/or inhibiting translation of target mRNAs (20). 
miRNAs have been implicated in many biological processes, including development, cell proliferation 
and neoplasia, glucose homeostasis, and lipid metabolism (21–25). miRNA-dependent regulation has 
been reported in pancreatic islets, liver, and adipose tissue in various model systems. For example, miR-
375 regulates pancreatic insulin secretion (26, 27), mir-103 and mir-107 influence insulin sensitivity in 
peripheral tissues (28), and mir-143 and mir-145 are up-regulated in the livers of genetic and dietary 
mouse models of obesity, whereas deficiency in the mir-143/145 cluster protects from the development of 
obesity-associated insulin resistance (29, 30). In addition, miRNAs of the let-7 family have been shown to 
participate in the regulation of glucose metabolism. Mice overexpressing let-7 had decreased fat mass and 
body weight (BW), as well as reduced body size. Global and pancreas-specific overexpression of let-7 in 
mice also resulted in impaired glucose tolerance and reduced glucose-induced pancreatic insulin secretion 
(31). In the same way, global knockdown of the let-7 family prevented and treated impaired glucose 
tolerance in mice with diet-induced obesity, at least in part by improving the insulin sensitivity in liver 
and muscle (24). 
As mentioned above, the hypothalamus is key in the regulation of energy and BW homeostasis. 
However, despite recent evidence suggesting the deregulation of various miRNA systems in peripheral 
tissues in conditions of metabolic disturbance, the possibility of perturbed expression of hypothalamic 
miRNAs in conditions of nutritional or metabolic stress, neither the potential alterations of hypothalamic 
miRNA expression in situations of leptin nor insulin resistance, has not been thoroughly addressed. In the 
present work, we performed an analysis of the miRNA expression profiles using a TaqMan Low Density 
miRNA array in the hypothalamus of rats reared with a normal diet (ND), a high-fat diet (HFD), and 
caloric restriction (CR) during 3 months after weaning. Based on high-throughput screening and 
bioinformatics predictions of their involvement in insulin-, leptin- and adiponectin-signaling pathways, 
the expression profiles of let-7a, mir-9*, mir-30e, mir-132, mir-145, mir-200a, and mir-218 were further 
analyzed in several models of altered metabolism. 
Materials and Methods 
Animals 
All experiments and animal protocols involved in this study were reviewed and approved by the ethics 
committees of the University of A Coruña and Complexo Hospitalario Universitario de A Coruña, in 
accordance with European Union Normative for the use of experimental animals. Male Wistar rats of 
different ages were used in this study and housed in a temperature-controlled room with a 12-hour light 
and 12-hour dark cycle (lights on from 8:00 am to 8:00 pm). Groups of rats born on the same day were 
used; on the day of birth, the animals were pooled at random and were evenly distributed between the 
dams to be bred in litters of 11 to 12 pups per dam. All rats were provided with ad libitum access to 
water. 
Body composition and tissue dissection 
Three days before killing, rat BW and composition were analyzed. Body fat and lean mass were 
measured by nuclear magnetic resonance with the EchoMRI method (Echomedical System). In addition, 
liver and visceral and epididymal WAT were dissected and weighed. Somatic indices were calculated as 
the ratio between tissue weight and BW and are expressed as a percentage. Rats were killed by cervical 
dislocation, and trunk blood was extracted. The hypothalami were dissected and stored at −80°C until 
further processing for real-time PCR or microarray assays. The hypothalamus was defined by the 
posterior margin of the optic chiasm and the anterior margin of the mammillary bodies to the depth of 
approximately 2 mm, following previous references (32). 
  
Bioinformatics analysis 
miRNAs are small endogenous RNAs that pair to sites in mRNAs to direct posttranscriptional 
repression. Many sites that match the miRNA seed (nucleotides 2–7), particularly those in 3′ untranslated 
regions, are preferentially conserved (33). Computational methods play important roles in the 
identification of new miRNAs and their targets. To search potential targets for a specific miRNA or 
potential regulators for a specific protein, we used five bioinformatics algorithms jointly: TargetScan, 
http://www.targetscan.org/ (34); miRanda, http://www.microrna.org/microrna/home.do (35); PicTar, 
http://pictar.mdc-berlin.de/ (36); Diana Lab, http://diana.cslab.ece.ntua.gr/microT/ (37); and miRWalk 
http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/ (38). Subsequently, pathway analysis was 
performed using the putative target gene list derived from the above cited bioinformatics algorithms. This 
analysis was performed using Ingenuity Pathway Analysis software (Ingenuity Systems, 
http://www.ingenuity.com/), generating a canonical pathway analysis. The networks are given a score 
based on the probability of inclusion of the number of molecules in the generated networks over the 
probability of a network being generated by chance with random molecules. This score is generated as a 
negative log P value. Canonical pathway analysis is performed by comparing the data set of interest 
against known canonical (signaling and metabolic) pathways within the database. 
Quantitative real-time PCR 
For assays of miRNAs, total RNA was extracted with an mirVana miRNA Isolation Kit (Ambion, 
Inc). Quality and concentration of the RNA were determined by agarose gel and a NanoDrop 
spectrophotometer ND-1000 (Thermo Scientific), respectively. Real-time PCR was performed on a Roche 
Light Cycler 480 real-time PCR detection system. cDNA was synthesized by using 10 ng of total RNA 
with TaqMan-specific RT primers and a TaqMan miRNA reverse transcription kit (Applied Biosystems). 
Thereafter, quantitative real-time PCR was performed using predesigned assays (Applied Biosystems). 
PCR reactions were performed as follows: 50°C for 2 minutes, 95°C for 10 minutes, followed by 40 
cycles of 95°C for 15 seconds and 60°C for 1 minute. For data analysis, relative standard curves were 
constructed from serial dilutions of one reference sample cDNA, and the input value of the target gene 
was standardized to RNU6 levels in each sample. The samples and standard curves were analyzed in 
duplicate. 
miRNA microarray assays 
miRNA microarray assays were performed with TaqMan Array Rodent MicroRNA Cards (Applied 
Biosystems). Comprehensive coverage of Sanger miRBase v15 is enabled across a 2-card set of TaqMan 
Array MicroRNA Cards for a total of 641 miRNAs. In addition, each card contains 5 candidate 
endogenous control assays and 1 negative control assay. Extraction of RNA and synthesis and 
amplification of cDNA were performed according to the manufacturer's instructions 
(http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocuments/cms_04232
6.pdf). 
Plasma measurements 
Insulin (Millipore), leptin, and adiponectin (Abcam) levels were measured by commercially available 
ELISAs, according to the specifications of the manufacturers. Plasma glucose and triglyceride levels were 
assessed using a commercial kit based on a colorimetric method (Spinreact). 
Experimental designs 
Hypothalamic miRNA profiling in rats reared with different diets: long-term experiments (experiment 1) 
To define the hypothalamic miRNA profiles and their possible variation with different BW, percent 
fat mass, insulin sensitivity, and other obesity-related factors, 30 male Wistar rats were used. At weaning 
day (postnatal day 21), with a mean BW of 98.1 ± 1.57 g, the animals were divided into 3 groups: (1) 
control group, with ad libitum access to standard chow diet (3.85 kcal/g; 10% kcal percent fat; Research 
Diets, Inc) (n = 10); (2) diet-induced obesity (DIO) group, with ad libitum access to an HFD diet (4.73 
kcal/g; 45% kcal percent fat; Research Diets, Inc) (n = 10); and (3) CR group (n = 10), with a standard 
chow diet, but with food restricted to 65% of the daily amount ingested by the control group. To this CR 
group, a fixed amount of food was provided daily, and the animals ate all the food offered. This feeding 
regimen was chosen for obtaining animals with lower percentages of body fat and increased sensitivity to 
insulin. The animals were housed under these feeding regimens until they were killed after 3 months. 
Animals were killed at 10:00 am, 2 hours after the beginning of the light phase. miRNA microarray 
assays were performed for 4 animals of each group. 
The array results were confirmed by individual assays for selected miRNAs. Once array results were 
confirmed and validated, we selected a small group of miRNAs to analyze in the subsequent studies, 
taking into account their degree of expression in the hypothalamus, their possible targets (obtained by 
computational approximations), and previous studies in other tissues. 
Alterations in hypothalamic miRNAs by fasting and different diets: short-term and midterm experiments 
(experiment 2) 
It is well known that an HFD is an important inducer of insulin resistance, and in rats, different 
manipulations of feeding have been shown to have various impacts on hypothalamic metabolism, 
although the nature of such changes depends on the type and timing of the nutritional challenge (39, 40). 
In experiment 2, we evaluated the impact of the HFD during 2 weeks or 1 month on a set of hypothalamic 
miRNAs. To this end, adult rats (BW of 260 ± 4 g, 11 weeks of age) were fed with the HFD or ND. The 
rats were killed 15 and 30 days after the beginning of the feeding with the HFD. 
Effects of leptin on hypothalamic miRNAs in fed and fasted rats (experiment 3) 
To monitor changes in hypothalamic miRNA expression in conditions of altered leptin signaling, we 
performed experiment 3, in which one group of adult rats (189 g ± 9 g, 9 weeks of age) was fed ad 
libitum and another group was deprived of food for 48 hours. Fed (with normal values of insulin, leptin, 
and glucose) and fasted (state associated with low levels of insulin, glucose, and leptin) rats received 2 ip 
injections of leptin (ProSpec, 1 mg/kg dissolved in 200 μL of saline) or vehicle. Injections were given at 
24 and 48 hours after the beginning of fasting. Treatments were started at 8:00 am and were performed in 
the light phase. Animals were killed 2 hours after the second injection (10:00 am). 
Statistical analysis 
Data were analyzed using SigmaStat 3.1 (Systat Software, Inc) and are expressed as a percentage of 
the control group in each experiment (means ± SEM). Statistical significance was determined by the 
Student t test (experiments with 2 groups), one-way ANOVA with a post hoc Tukey test (experiments 
with more than 2 groups and 1 variable), or two-way ANOVA with a post hoc Tukey test (experiments 
with 2 or more groups and 2 variables). A value of P ≤ .05 was considered significant. Different 
superscript letters or asterisks indicate statistical significance. 
Results 
Hypothalamic miRNA profiling in rats reared with different diets: long-term experiments 
Effect of different diets on BW and composition 
Major body parameters, including percent fat and lean body mass as well as BW gain during the 3-
month period of nutritional manipulation, are shown in Figure 1, A to C. The percentage of fat mass was 
very low in animals subjected to CR (scarcely 2%) but was 9.5% in the control group and rose to 18.8% 
in HFD animals (Figure 1A). On the contrary, the percentage of lean mass decreased as an inverse 
function of the feeding regimen; the highest percentage was seen in CR rats and the lowest in HFD 
animals, although net differences were not as obvious (Figure 1B). As expected, total BW gain was 
maximal in HFD rats, whereas CR animals displayed the lowest BW gain during the study period (Figure 
1C). 
  
 
 
 
Figure 1. Effect of the HFD and CR during 3 months on percent body fat mass (A), percent body lean mass (B), body weight gain 
(C) and plasma glucose (D), insulin (E), adiponectin (F), leptin (G), and triglyceride (H) levels. Different letters above the bars 
indicate statistical differences. A value of P ≤ .05 was considered statistically significant (one-way ANOVA with a post hoc Tukey 
test). CR, n = 10; ND, n = 10; and HFD, n = 10. 
Plasma parameters 
To monitor the potential metabolic alterations induced by the different diets, we analyzed different 
plasma parameters. As shown in Figure 1, D to H, animals subjected to CR displayed signs of increased 
insulin sensitivity because they had lower basal glucose (Figure 1D) and insulin (Figure 1E) levels and 
enhanced adiponectin concentrations (Figure 1F) compared with those of the control (ND) and HFD 
groups. In contrast, HFD rats presented signs of insulin resistance and metabolic deregulation, as 
evidenced by higher basal glucose, insulin, and leptin (Figure 1G) levels, together with increased plasma 
triglyceride concentrations (Figure 1H) and decreased adiponectin levels. 
Microarray profiling of hypothalamic miRNA expression and changes related to different diets 
To investigate the global hypothalamic profiles of miRNAs and their potential changes under different 
nutritional manipulations (HFD and CR), we used a high-throughput approach based on TaqMan Low 
Density miRNA Array technology. Of the 641 miRNAs analyzed, 326 were found to be expressed in the 
hypothalamus. The miRNA profiles obtained in normal rats are shown in Figure 2A, organized according 
to relative expression levels, from the lowest to the highest expression. For a more detailed presentation 
and analysis of data, see Supplemental Table 1 published on The Endocrine Society's Journals Online 
web site at http://jcem.endojournals.org. In addition, comparative expression profiling of miRNA 
signatures in hypothalami from rats subjected to CR or the HFD was conducted. In at least one nutritional 
manipulation, 74 miRNAs were deregulated. Fold change and statistical significance are reported in 
Figure 2B and Supplemental Table 2. These miRNAs belong to 63 different miRNA families, of which 
29 are broadly conserved, 15 are conserved, and 19 are poorly conserved across mammalian species. 
Among the widely conserved families that were affected by diet regimens, it is worth noting that 6 of 10 
members of the mir-30 family were altered by nutritional manipulations, whereas 4 of 5 members of the 
mir-200bc family and several let-7 miRNAs were deregulated after persistent nutritional challenge. 
  
 
 
 
Figure 2. Heat map of miRNA microarray data displaying expression profiles in the adult male rat hypothalamus. A, Expression of 
each miRNA was calculated by the ΔΔCt method, using the RNU6 gene as internal reference. Expression is given in arbitrary units 
and is the mean of four samples. To facilitate interpretation of the results, the first 5 columns have a scale different from that for the 
last column. B, Overview of the miRNAs that show statistically significant differences in at least one treatment in the adult male rat 
hypothalamus reared with different diets. The expression intensity of each miRNA varies from blue to red. Expression is given in 
arbitrary units and is the mean of four samples, where ND = 100%. Row labels on the left side of the image indicate significant 
different types. A value of P ≤ .05 was considered statistically significant (one-way ANOVA with a post hoc Tukey test). In all 
cases, the animals were reared with feeding of these diets during the 3 months after weaning. Data were plotted using matrix2png 
1.2.2 (http://www.chibi.ubc.ca/matrix2png/).  
  
After high-throughput screening, individual quantitative PCR validation was implemented using the 
same samples, an approach that demonstrated high reproducibility of our expression assays. Of note, 
however, the actual magnitude of the (fold) increase or decrease displayed some variance between 
individual quantitative PCR and the TaqMan Low Density miRNA array technology. In particular, mir-
145 and mir-9* showed statistically significant differences when the analysis was conducted individually, 
with higher values in HFD rats compared with ND/CR animals. Likewise, let-7a was up-regulated in 
HFD vs ND rats. Results from targeted miRNA assays are shown in Figure 3. Note that, for the sake of 
simplicity, presentation of analyses is grouped into categories, depending on the type and magnitude of 
changes after nutritional manipulation. Thus, in Figure 3, top panel, miRNAs whose expression levels 
increase only with HFD (let-7a, mir-9*, mir-30b, mir-100a, and mir-145) are shown. In Figure 3, middle 
panels, we display miRNAs whose expression levels increase only with CR (mir-29a, mir-30e, mir-323-
3p, and mir-374-5p). Furthermore, miRNAs that are increased in expression with either HFD or CR (mir-
132, mir-218, and mir-539) are presented Figure 3, middle panels. Finally, in Figure 3, bottom panel, 
miRNAs that are down-regulated at the hypothalamus after CR (mir-200a, mir-200b, and mir200c) is 
presented.  
 
 
 
Figure 3. Real-time PCR validation of several miRNAs of interest. Values are expressed in arbitrary units 
(means ± SEM), where ND = 100%. Different letters above the bars indicate statistical differences (ANOVA 
with a post hoc Tukey test). CR, n = 5; ND, n = 5; and HFD, n = 5. The animals were reared with consumption 
of these diets during 3 months after weaning. 
  
For further studies, we chose 7 miRNAs among those significantly deregulated by CR and/or HFD 
(let-7a, mir-9*, mir-30e, mir-132, mir-145, mir-200a, and mir-218). We selected these miRNAs for 3 
reasons: (1) because their hypothalamic expression is high; (2) because previous studies in other tissues 
linked them with metabolic alterations; and (3) because of data from informatics models, which suggested 
that they are involved in the regulation of the signaling pathways of insulin, leptin, or adiponectin, fatty 
acid or lipid metabolism, and/or inflammation (Figure 4, Supplemental Figure 1, and Supplemental Table 
3). 
 
 
 
Figure 4. Schematic representation of the interrelation between let-7a, mir-9*, mir-30e, mir-132, mir-145, mir-200a, and mir-218 
and genes related to insulin, leptin, and adiponectin signaling pathways. Analysis was performed with ingenuity pathway analysis 
software. ADIPOR2, adiponectin receptor 2; INSR, insulin receptor; IRS1, insulin receptor substrate 1; IRS2, insulin receptor 
substrate 2; LEPR, leptin receptor; mTOR, mammalian target of rapamycin; RICTOR, rapamycin-insensitive companion of mTOR; 
SOCS3, suppressor of cytokine signaling 3. Arrows indicate positive interactions, whereas arrows with T-bars indicate negative 
interactions. Solid lines indicate direct interactions, and dotted lines indicate indirect interactions. 
Bioinformatics analysis 
For the set of miRNAs indicated above (let-7a, mir-9*, mir-30e, mir-132, mir-145, mir-200a, and mir-
218), we conducted analyses using up to 5 different bioinformatics algorithms to predict putative target 
genes/pathways. Of note, the various bioinformatics tools identified slightly different targets. 
Nonetheless, comparison between analyses and algorithms allowed us to select gene targets identified by 
at least three different programs; results are shown in Supplemental Table 3. Finally, the top scoring 
canonical pathways corresponding to identified targets for let-7a, mir-9*, mir-30e, mir-132, mir-145, mir-
200a, and mir-218 are shown in Supplemental Figure 1. For all the miRNAs studied, except mir-200a, 
some of the pathways with the highest score are related to neuronal development, such as axonal guidance 
signaling, semaphorin signaling, ephrin receptor signaling, and dendritic cell maturation. For mir-132 and 
mir-218, neuronal cAMP-response element binding protein (CREB) signaling also displayed high scores. 
Notably, CREB-dependent gene expression has been involved in many different aspects of nervous 
system function (41, 42). Moreover, signaling pathways disturbed in obesity, such as nuclear factor κβ, 
ILs, phosphatidylinositol 3-kinase/serine-threonine protein kinase (AKT), ceramide, insulin receptor, 
p70S6K, and Janus tyrosine kinase/signal transducer and activator of transcription, were also found 
among the top scoring canonical pathway targets of the selected miRNAs (Supplemental Figure 1). 
  
Diet-induced alterations in hypothalamic miRNAs: short-term and midterm experiments 
Effect of different diets on BW and composition and plasma parameters 
Major body parameters and plasma levels of key factors in rats fed during 2 weeks and 1 month with 
different diets are shown in Table 1. As expected, BW gain was greater in animals fed with the HFD. In 
turn, whereas glucose levels were higher in HFD rats after 2 weeks of diet, at the end of the 1-month 
period circulating glucose concentrations were lower than in controls, probably due to the trend for higher 
levels of insulin in HFD animals, which, nonetheless, was not statistically significant. The HFD did not 
alter the liver somatic index, but significantly increased the visceral and epididymal somatic indices at the 
2 time points studied (Table 1). 
Table 1. Effects of a HFD During 2 Weeks or 1 Month on Body Weight Gain, Plasma Glucose, Insulin, and Triglyceride Levels and 
Somatic Indices 
     Somatic Index, % 
 
Body Weight 
Gain, g  
Glucose, 
mg/dL  
Insulin, 
ng/mL  
Triglycerides, 
mg/dL  
Liver  Epididymal  Visceral  
        
ND, 2 wk  41.2 ± 2.5 120 ± 1.5 2.3 ± 0.3 162 ± 13 3.7 ± 0.1 0.96 ± 0.05 0.68 ± 0.04 
HFD, 2 wk  69.8 ± 2.1a 134 ± 4.2a 2.9 ± 0.4 129 ± 24 3.7 ± 0.1 1.43 ± 0.08a 0.97 ± 0.04a 
ND, 1-mo  192.3 ± 6.6 138.42 ± 1.9 3.5 ± 0.5 151 ± 9 4.18 ± 0.08 1.28 ± 0.09 1.01 ± 0.05 
HFD, 1-mo  228.5 ± 6.9a 124.5 ± 5.4a 4.3 ± 0.4 146 ± 14 3.99 ± 0.09 2.49 ± 0.21a 1.60 ± 0.09a 
        
 
a, P < .05 vs ND. Somatic index was calculated as the ratio between tissues weight and body weight and was expressed as a 
percentage. 
Hypothalamic miRNA expression 
Based on results from long-term nutritional manipulations (including the HFD), the hypothalamic 
expression levels of the set of miRNAs selected from long-term experiments (let-7a, mir-9*, mir-30e, 
mir-132, mir-145, mir-200a, and mir-218) were also assayed in male rats subjected to the HFD for 2 
weeks or 1 month and compared with data obtained in rats exposed to the HFD for 3 months in the 
previous experiment. The time course of the HFD-induced changes in those miRNA targets is shown in 
Figure 5. Our analyses showed that mir-30e, mir-145, and mir-218 miRNA levels in the hypothalamus 
were similarly deregulated by the HFD, with an initial suppression followed by a variable increase in 
hypothalamic expression, which become significant after 1 month for mir-218 and after 3 months for mir-
145. On the other hand, hypothalamic let-7a and mir-9* expression levels were consistently elevated by 
the HFD, whereas mir-132 expression was enhanced only at 3 months after the HFD. In contrast, mir-
200a expression in the hypothalamus decreased in animals fed with the HFD for 2 weeks and 1 month, 
but its miRNA levels returned to control values at 3 months after HFD exposure (Figure 5). 
 
 
 
Figure 5. Effect of HFD during 2 weeks (n = 9), 1 month (n = 8), and 3 months (n = 5) on let-7a, mir-9*, mir-30e, mir-132, mir-
145, mir-200a, and mir-218 miRNA expression levels in the hypothalamus of adult male rats. Values are expressed in arbitrary units 
as means ± SEM. For each time point, HFD values are expressed as a percentage of animals fed with the ND (100%, dotted line). 
Asterisk above the bars indicate statistical differences (Student t test). In all cases, the animals were killed between 3 and 4 months 
of age. 
Effect of leptin on hypothalamic expression of selected miRNAs and mRNAs in fed and fasting rats 
Effect of leptin on body weight/composition and plasma parameters 
The impact of leptin on various somatic and metabolic parameters was evaluated in rats fed ad libitum 
or subjected to a 48-hour fast. Food deprivation evoked the expected decreases in BW, glucose, insulin, 
triglycerides, and the liver somatic index. Fed rats treated with leptin for 48 hours (2 boluses, 24 hours 
apart) displayed a significant decrease in food intake (Figure 6A), so that, in contrast with control 
animals, leptin-injected animals fed ad libitum lost weight during the treatment period (Figure 6B). In 
addition, leptin-treated rats fed ad libitum had significantly lower glucose levels than the control group 
(Figure 6C), whereas their insulin levels tended to be higher (Figure 6D). Leptin treatment diminished 
triglyceride levels both in fed and fasted animals (Figure 6E). Finally, although liver and visceral somatic 
indices were not altered by leptin, leptin tended to diminish the epididymal somatic index, which was 
further decreased by leptin in fasted animals (Figure 6, F–H). 
 
 
 
Figure 6. Effect of a single ip leptin injection on cumulative food intake during 3 and 24 hours after treatment (A) and the effect of 
2-day ip leptin treatment in fed and fasted animals on body weight (B), plasma glucose (C), insulin (D), and triglyceride (E) levels, 
and liver (F), visceral WAT (G), and epididymal WAT (H) somatic indexes. *, P ≤ .05 vs fed; #, P ≤ .05 vs. control (rats injected 
with saline). Values are expressed as means ± SEM; n = 7 to 8 (two-way ANOVA with a post hoc Tukey test). Somatic indexes 
were calculated as the ratio between tissue weight and body weight and was expressed as a percentage.  
Effect of leptin on selected hypothalamic miRNA expression 
Fasting caused an increase in let-7a, mir-132, mir-145, and mir-9* miRNA expression levels in the 
hypothalamus, an effect that was completely reversed by treatment with leptin (Figure 7). In turn, leptin 
treatment increased mir-218 and mir-9* miRNA expression levels in rats fed ad libitum, whereas the 
effect of leptin was the opposite in rats subjected to fasting. Likewise, mir-30e expression levels remained 
unchanged after treatment with leptin in fed rats but decreased after leptin administration to fasted rats 
(Figure 7). There were no changes of any type for mir-200a, mir-29a, and mir-31 (Figure 7). 
 
 
 
Figure 7. Effect of 2-day leptin treatment on let-7a, mir-9*, mir-30e, mir-132, mir-145, mir-200a, and mir-218 miRNA expression 
levels in hypothalamus of adult male rats in fed and fasted conditions. Values are expressed in arbitrary units as means ± SEM (n = 
7–8) and as percentage of fed controls (fed animals treated with saline = 100%). *, P ≤ .05 vs fed; #, P ≤ .05 vs control (rats injected 
with saline) (two-way ANOVA with a post hoc Tukey test). - See more at: http://press.endocrine.org/doi/full/10.1210/en.2013-
1770#sthash.UuCnX4Gk.dpuf 
Discussion 
Obesity is a major health problem and is reaching pandemic proportions in both developed and 
developing countries. The hypothalamus plays a key role in energy homeostasis by controlling food 
intake and sensing multiple peripheral metabolic signals, such as leptin, insulin, adiponectin, gut 
hormones, and nutrients that interact with specific hypothalamic regions to modulate central and 
peripheral metabolic pathways (8–10). However, the ultimate molecular mechanisms whereby such 
hypothalamic integration is conducted remain largely unknown. In this scenario, the possibility that 
miRNA regulatory pathways participate in the central control of energy homeostasis is appealing but has 
yet to be characterized. In fact, although different miRNAs have been related to the control of metabolism 
in vertebrates (43–46), their involvement in such function at hypothalamic levels remains unexplored. By 
the use of microarray analysis followed by quantitative PCR validation, in this study we intended to 
characterize changes in the hypothalamic miRNA signature in different nutritional and metabolic 
conditions, including HFD-induced obesity, chronic CR, and leptin treatments. 
Our analyses documented the expression of 327 miRNAs in the hypothalamus, with up to 74 being 
deregulated by chronic CR and/or the HFD. Of note, recent studies in rats identified strong expression of 
miRNAs of the let-7, mir-7, mir-9, and mir-30 families in discrete hypothalamic nuclei, such as the 
arcuate and paraventricular nuclei (47, 48). These miRNAs were also highly expressed in whole 
hypothalamic fragments in our study; however, the greatest expression levels in present analyses were 
detected for mir-29a and mir-9, followed by mir-30b, mir-126-3p, mir-9*, mir-26a, mir-191, mir-138, 
mir-149, mir-125b-5p, mir-24, mir-434-3p, mir-539, and mir-132. 
The miRNAs that were deregulated by long-term nutritional challenges (HFD or/and CR) belong to 
63 different families, 29 of which are broadly conserved across mammalian species. For operational 
reasons, of the total set of altered targets, we focused further analyses on a subset of 7 miRNAs; these 
included (1) mir-30e, whose family showed 6 of its 10 members altered in our array studies; (2) let-7a, 
which belongs to a family with several members deregulated and previously related with the control of 
glucose metabolism and insulin sensitivity (24, 31); (3) mir-9* and mir-132, which are brain-specific 
miRNAs with high hypothalamic expression; (4) mir-145, which related with insulin and glucose 
metabolism in peripheral tissues in obesity (30); (5) mir-218, which has been linked to the inhibition of 
AKT phosphorylation (49, 50); and (6) mir-200a, which, together with mir-200b and mir-200c, was the 
miRNA that displayed a greater fold change in our arrays and whose alteration has been linked to 
predisposition to develop overweight in rats after early leptin blockade (51). 
In addition to the reasons listed above, different bioinformatic models pointed out that these miRNAs 
target and putatively regulate elements of pathways related with neuronal development, neuronal CREB 
signaling, and, more importantly, insulin, adiponectin, leptin, and inflammation signaling pathways. For 
instance, all miRNAs studied individually in this work, except mir-145, are seemingly involved in some 
(or several) steps of neurogenesis (52–59). Similarly, participation of these miRNAs in inflammatory 
signaling provides a tenable link with obesity, because this is now considered an inflammatory disease 
that results from the consolidation of a state of low-grade inflammation in the hypothalamus. Such an 
inflammatory state would contribute to the resistance to the effects of leptin and insulin (60, 61) and to 
alteration of neuronal circuits in the hypothalamus (for a review, see Ref. 6). 
miRNA expression analyses together with metabolic profiling in our models of metabolic stress 
allowed us to identify 2 stages during the progression of diet-induced obesity: (1) an early phase during 
the first few weeks of the HFD; and (2) a chronic period, when obesity and associated metabolic 
alterations were clearly established. During the initial stage, several miRNAs showed a decline in their 
expression levels (mir-30e, mir-145, mir-200a, and mir-218), which were normalized over time (mir-
200a) or even displayed an increase at later periods (mir-218, mir-145, and mir-30e). These late responses 
may be reactive or secondary to the primary metabolic insult, as an attempt to restore metabolic 
homeostasis against the metabolic deregulation that occurs when obesity gets consolidated and 
hypothalamic insulin, leptin, or inflammation signaling is primarily disturbed (62–65). Different 
manipulations of feeding have been shown to have a variable impact on hypothalamic metabolism, 
although the nature of such changes depends on the type and timing of the nutritional challenger (39, 40). 
Therefore, we cannot rule out the possibility that some of the differences observed during the 
development of DIO were due to the age at which the animals were exposure to the HFD rather than to 
the duration of this diet. Nonetheless, because we have previously shown that some of our miRNA targets 
vary their hypothalamic expression levels along postnatal development (32), HFD exposures in the 
different DIO groups were adjusted in such a way that that all animals were sampled in adulthood. 
Although our high-throughput data did not permit us to demonstrate a direct causal link between the 
observed changes in hypothalamic expression of the selected miRNAs and the malfunction of central 
pathways, potentially altered in extreme metabolic conditions, bioinformatics predictions allowed us to 
set educated hypothesis for tenable hubs where this pathogenic connection may take place. For instance, 
compelling experimental evidence has demonstrated that hypothalamic insulin and leptin resistance is 
associated with decreased AKT activity (66, 67) and high levels of suppressor of cytokine signaling-3 
(SOCS3) (68, 69). In this context, algorithm predictions suggest that miR-218 and mir-30 miRNA families 
are potential regulators of SOCS3, whereas mir-143/145, mir-132, mir-30, and mir-218 families are 
possible regulators of oxysterol binding protein-like 8, a protein that promotes insulin-stimulated AKT 
activation and is expressed at high levels in the brain (30). Furthermore, mir-218 and let-7 miRNAs have 
been proposed to target the mammalian target of rapamycin component, RICTOR, thereby inhibiting 
AKT phosphorylation (49, 50), whereas let-7 miRNAs regulate glucose metabolism in peripheral tissues 
by decreasing the protein expression levels of insulin receptor, insulin receptor substrate 2, TORC1, IGF-
I, and IGF-I receptor (24, 31). Therefore, the observed increase in the expression levels of these miRNAs 
during development of obesity might induce a decline in the activation of AKT (and hence leptin/insulin 
resistance) by regulating RICTOR and/or oxysterol binding protein-like 8. 
Similarly, it is interesting to note that our models of high hypothalamic expression of SOCS3, such as 
long-term HFD or leptin treatment (our unpublished observations), displayed increased mir-218 and mir-
30e miRNA expression levels in the hypothalamus. Assuming a repressor role of these miRNAs on 
SOCS3 expression, it is tempting to speculate that these responses may be set to decrease SOCS3 mRNA 
levels as a means to relieve its negative effects on leptin/insulin signaling in the long term. On the other 
hand, mir-218 has been shown to inactivate the proinflammatory nuclear factor κβ pathway in glioma 
cells (70, 71), whereas brain inflammation up-regulated mir-132, which in turn promoted anti-
inflammatory responses (72). On this basis, it is tenable that the increases in mir-218 and mir-132 
expression after long-term HFD exposure might be a mechanism to alleviate excessive inflammation that 
is likely to occur in conditions of persistent obesity. 
Admittedly, the magnitude of some of the changes in hypothalamic miRNA expression reported here, 
although statistically significant, are of moderate magnitude, a feature that may call for caution when the 
functional relevance of such modifications is interpreted. We believe, however, that part of such modest 
changes are due to our analytic approach, in which large-scale microarray analyses were applied to whole 
hypothalamic fragments. Thus, notable changes in discrete hypothalamic nuclei/areas might be partially 
obscured or compensated. Although this is a limitation of our approach, it is fair to assume that the 
observed changes are genuine and point out specific deregulated pathways, whose precise location and 
functional relevance would require targeted characterization in subsequent studies. In any event, we do 
believe that our array data followed by targeted expression analyses in different preclinical models of 
metabolic distress has translational value and permit initial identification of appealing candidates for such 
follow-up studies. 
In conclusion, by the use of a combination of preclinical models of severe metabolic distress, our 
present study is the first to document changes in hypothalamic miRNA expression profiles in conditions 
of overweight, chronic CR, and leptin treatment. Notably, the deregulated miRNAs displayed different 
time-course alterations in their expression patterns after potent obesogenic insults (such as an HFD) and 
were identified by different computational algorithms as putative regulators of genes encoding key factors 
in insulin and leptin signaling, as well as in neurogenesis and inflammation. Although further functional 
analyses of such pathophysiological connections is still pending, our study brings new insights into the 
potential roles of several miRNAs in the mechanisms whereby the hypothalamus primarily controls and 
adapts to dynamic fluctuations in energy homeostasis and highlights the potential role of miRNA 
regulatory pathways as a possible link (and eventual therapeutic target) for obesity, inflammation, and 
neurodegenerative diseases. 
Abbreviations:  
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